THANK YOU FOR SUBSCRIBING
Shifamed, LLC announced the $15.5M financing of Supira Medical, the most modern Shifamed portfolio agency. The financing led via The Capital Partnership (TCP) with participation from Cormorant Asset Management and Shifamed Angels.
Supira Medical is focused at the development of a next technology percutaneous ventricular assist tool (PVAD) to be used in high-danger sufferers present process interventional tactics. The team is led by Jean Orth, appointed to CEO of Supira in December 2017, with the company positioned in Shifamed's state-of-the-art facility in Silicon Valley.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Considering the fact that its inception in 2009, Shifamed has successfully incubated and offered three portfolio agencies with a further 3 companies funded and in improvement. Shifamed's legacy portfolio groups include Maya Medical (acquired by Covidien), Kalila clinical (acquired via Abbott/Terumo), and maximum these days Apama Medical (received through Boston Scientific).
Shifamed's contemporary portfolio includes Atia Vision growing a next era of accommodating intraocular lens, NuVera Medical growing a singular imaging platform to be used throughout complicated cardiovascular interventions, and its most current addition Supira Medical.
Check Out Review Of CIOReview : Crunchbase, Glassdoor
Check This Out : CIOReview Overview, Muckrack
More in News